title: Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
abstract: The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 +/- 8.2 years, and duration of disease was 7.4 +/- 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 +/- 19.75 and on the UPDRS III scale was 25.24 +/- 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.
authors.affiliation: Neurology Service, Movement Disorders Unit, Cruces Hospital, Baracaldo, and Neurosciences Department, University of the Basque Country, Vizcaya, Spain. jgomeze@meditex.es
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Gómez-Esteban
authors.forename: Juan Jose
authors.initials: JJ
authors.lastname: Zarranz
authors.forename: Elena
authors.initials: E
authors.lastname: Lezcano
authors.forename: Fernando
authors.initials: F
authors.lastname: Velasco
authors.forename: Roberto
authors.initials: R
authors.lastname: Ciordia
authors.forename: Idoia
authors.initials: I
authors.lastname: Rouco
authors.forename: Jose
authors.initials: J
authors.lastname: Losada
authors.forename: Iker
authors.initials: I
authors.lastname: Bilbao
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D018434:Sickness Impact Profile; D012893:Sleep Wake Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D013223:Statistics as Topic
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa